.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,126,941

« Back to Dashboard

Claims for Patent: 9,126,941

Title:Treatment of hyperproliferative disorders with diarylhydantoin compounds
Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s): Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Los Angeles, CA), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:13/448,964
Patent Claims: 1. A method for treating a cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of ##STR00238## or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the cancer.

2. The method of claim 1, further comprising administering an antiandrogen to the subject.

3. The method of claim 2, wherein the composition is administered at a dosage of the compound in a range selected from the group consisting of from about 0.001 mg per kg body weight per day to about 100 mg per kg body weight per day, from about 0.01 mg per kg body weight per day to about 100 mg per kg body weight per day, and from about 0.1 mg per kg body weight per day to about 10 mg per kg body weight per day.

4. The method of claim 2, wherein the composition is administered at a dosage of the compound of about 1 mg per kg body weight per day.

5. The method of claim 2, wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.

6. The method of claim 2, wherein the compound is in a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.

7. The method of claim 1, wherein the compound is ##STR00239##

8. The method of claim 1, wherein the compound is ##STR00240##

9. The method of claim 1, wherein the compound is ##STR00241##

10. The method of claim 2, wherein the compound is ##STR00242##

11. The method of claim 2, wherein the antiandrogen is selected from the group consisting of a non-steroidal antiandrogen and bicalutamide.

12. The method of claim 2, wherein the cancer is selected from the group consisting of prostate cancer, hormone sensitive prostate cancer, and hormone refractory prostate cancer.

13. The method of claim 2, wherein the cancer is prostate cancer and wherein administering the compound prevents the prostate cancer from progressing to hormone refractory prostate cancer.

14. The method of claim 2, wherein the cancer is hormone sensitive prostate cancer and wherein administering the compound prevents the hormone sensitive prostate cancer from progressing to hormone refractory prostate cancer.

15. The method of claim 2, wherein the cancer is selected from the group consisting of breast cancer, hormone sensitive breast cancer, and hormone refractory breast cancer.

16. The method of claim 2, wherein the cancer is breast cancer and wherein administering the compound prevents the breast cancer from progressing to hormone refractory breast cancer.

17. The method of claim 2, wherein the cancer is hormone sensitive breast cancer and wherein administering the compound prevents the hormone sensitive breast cancer from progressing to hormone refractory breast cancer.

18. The method of claim 2, wherein the cancer is selected from the group consisting of ovarian cancer, hormone sensitive ovarian cancer, and hormone refractory ovarian cancer.

19. The method of claim 1, further comprising administering an antiandrogen to the subject, wherein the compound is administered after administering the antiandrogen.

20. The method of claim 19, wherein the compound is ##STR00243##

21. The method of claim 19, wherein the antiandrogen is bicalutamide.

22. The method of claim 19, wherein the cancer is selected from the group consisting of prostate cancer, hormone sensitive prostate cancer, hormone refractory prostate cancer, breast cancer, and ovarian cancer.

23. The method of claim 1, further comprising administering an antiestrogen to the subject.

24. The method of claim 23, wherein the compound is ##STR00244##

25. The method of claim 23, wherein the cancer is selected from the group consisting of breast cancer, hormone sensitive breast cancer, and hormone refractory breast cancer.

26. The method of claim 23, wherein the cancer is breast cancer and wherein administering the compound prevents the breast cancer from progressing to hormone refractory breast cancer.

27. The method of claim 23, wherein the cancer is hormone sensitive breast cancer and wherein administering the compound prevents the hormone sensitive breast cancer from progressing to hormone refractory breast cancer.

28. The method of claim 23, wherein the cancer is selected from the group consisting of ovarian cancer, hormone sensitive ovarian cancer, and hormone refractory ovarian cancer.

29. The method of claim 1, further comprising administering an antiestrogen to the subject, wherein the compound is administered after administering the antiestrogen.

30. The method of claim 29, wherein the compound is ##STR00245##

31. The method of claim 29, wherein the cancer is selected from the group consisting of breast cancer and ovarian cancer.

32. The method of claim 1, further comprising administering a receptor modulator selected from the group consisting of an estrogen receptor modulator and a nuclear receptor modulator to the subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc